Promoting tumor cytotoxicity mediated by FAS-FASL might improve the therapeutic efficacy of CAR T cells directed against tumors with heterogeneous antigen expression and present a way to overcome therapeutic failure due to antigen loss. Here, FASLG is linked to neoplasm.